Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 4/20 | 0.35 |
| ▸ | HTR1D | P28221 | 3/20 | 0.35 |
| ▸ | HTR1B | P28222 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR1F | P30939 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8382026 | 0.84 | HTR6 (0.34) | MAPTHTR6LMNAPOLB | |
| SCHEMBL7483589 | 0.82 | KDM4E (0.50) | NOS3NOS1MAPTTP53HTR6 | |
| SCHEMBL7482247 | 0.81 | NOS3 (0.46) | NOS3NOS1MAPTTP53HTR6 | |
| SCHEMBL8383718 | 0.81 | NOS3 (0.43) | NOS3NOS1MAPTLMNAPOLB | |
| SCHEMBL30909307 | 0.81 | NOS3 (0.43) | NOS3NOS1MAPTLMNAPOLB | |
| SCHEMBL8387372 | 0.80 | NOS3 (0.44) | NOS3NOS1MAPTLMNAMEN1 | |
| SCHEMBL8386628 | 0.79 | NOS3 (0.40) | NOS3NOS1MAPTTP53HTR1D | |
| SCHEMBL8386372 | 0.79 | NOS3 (0.44) | NOS3NOS1HTR1DHTR1BHTR1A | |
| SCHEMBL8386551 | 0.78 | NOS3 (0.54) | NOS3NOS1MAPTHTR1DHTR1B | |
| SCHEMBL8381730 | 0.78 | TDP1 (0.46) | NOS3NOS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| US-5874427-A | MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | NOS3 1678/4885NOS1 1339/4885MAPT 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.